Barclays lowered the firm’s price target on Exscientia to $10 from $12 and keeps an Overweight rating on the shares. The analyst believes ESMO abstracts “helps de-risk” preclinical MALT1 and LSD1 inhibitors. With Exscientia’s pipeline re-prioritization, the firm removed adenosine from the model.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EXAI: